Connect with us

Hi, what are you looking for?

World

Carlyle offers J&J $4.15 bn for testing unit

-

Private equity firm Carlyle Group has agreed to buy Johnson & Johnson's Ortho-Clinical Diagnostics medical testing unit for $4.15 billion, J&J announced Thursday.

J&J said it will consult with works councils and trade unions over Carlyle's binding offer for OCD by the March 31 deadline.

Carlyle said it plans additional investment in OCD, which it intends to run as an independent company.

"Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation," said Carlyle Group managing director Stephen Wise in a statement.

"Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide."

J&J announced a year ago that it was considering a sale of the unit, which had around $2 billion in revenues in 2012, to focus on other products that offer better growth prospects.

J&J chief executive Alex Gorsky described the deal as resulting from "our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson."

OCD, with manufacturing facilities in the US and Wales, provides in-vitro diagnostic products that conduct screening and blood-typing to diagnose diseases and ensure transfusion patients receive the right type of blood.

The company also provides information management, testing technologies and automation tools to clinical laboratories.

J&J said if it accepts the Carlyle offer, it expects the transaction to close toward the middle of the year pending regulatory approval.

J&J was down 0.2 percent to $94.62 in midday trade, and Carlyle lost 0.1 percent to $36.94.

Private equity firm Carlyle Group has agreed to buy Johnson & Johnson’s Ortho-Clinical Diagnostics medical testing unit for $4.15 billion, J&J announced Thursday.

J&J said it will consult with works councils and trade unions over Carlyle’s binding offer for OCD by the March 31 deadline.

Carlyle said it plans additional investment in OCD, which it intends to run as an independent company.

“Ortho-Clinical Diagnostics is an established global brand with a reputation for quality and innovation,” said Carlyle Group managing director Stephen Wise in a statement.

“Through accelerated investment in research and product development and continued expansion into both emerging and established markets, we expect to tap into rising demand for sophisticated medical diagnostic products and services worldwide.”

J&J announced a year ago that it was considering a sale of the unit, which had around $2 billion in revenues in 2012, to focus on other products that offer better growth prospects.

J&J chief executive Alex Gorsky described the deal as resulting from “our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson.”

OCD, with manufacturing facilities in the US and Wales, provides in-vitro diagnostic products that conduct screening and blood-typing to diagnose diseases and ensure transfusion patients receive the right type of blood.

The company also provides information management, testing technologies and automation tools to clinical laboratories.

J&J said if it accepts the Carlyle offer, it expects the transaction to close toward the middle of the year pending regulatory approval.

J&J was down 0.2 percent to $94.62 in midday trade, and Carlyle lost 0.1 percent to $36.94.

AFP
Written By

With 2,400 staff representing 100 different nationalities, AFP covers the world as a leading global news agency. AFP provides fast, comprehensive and verified coverage of the issues affecting our daily lives.

You may also like:

Business

Less obvious is exactly how well-balanced this vast range of credit plays and Big Capital can possibly be.

Entertainment

Wearing headphones and anti-sweat finger sleeves, gamers from eight countries guided gun-toting avatars through the Saudi battle royale.

Business

JuicyFields offered returns of up to 66 percent - Copyright AFP/File BAY ISMOYOSpain’s top criminal court has opened a fraud investigation into a Netherlands-based...

Business

Canada launched a long-awaited review of its cannabis regulations four years after legalizing its recreational use.